Baltimore, Walgreens Reach Opioid Settlement Totaling $402.5m
Baltimore, Walgreens Reach Opioid Settlement Totaling $402.5m
Introduction
The City of Baltimore has reached a settlement with Walgreens over its involvement in the opioid crisis, marking the fifth settlement in the City’s six-year legal battle against opioid distributors and manufacturers.
The full terms of the settlement will be disclosed on October 3, 2024.
This agreement follows previous settlements with Allergan and CVS for $45 million each, Teva for $80 million, and Cardinal Health for $152.5 million, bringing the City’s total opioid-related recoveries to $402.5 million. The remaining cases against Johnson & Johnson, McKesson, and AmerisourceBergen are set to go to trial next week.
City Solicitor explained that Walgreens requested a 30-day delay in announcing the settlement details, which the City agreed to in order to focus on the upcoming trial against other key defendants in the opioid epidemic.
Baltimore's mayor praised the legal efforts, emphasizing the need for substantial resources to combat the opioid crisis. The funds from these settlements will help bolster ongoing initiatives aimed at addressing the epidemic and providing support where it's most needed.
The outside legal team working with the City also expressed pride in the progress made and readiness for the upcoming trial.
Comments
Latest News
Cencora Directors Settle Opioid Oversight Case for $111M
Categories: Opioids
Cencora has agreed to pay $111.3 million to settle a shareholder lawsuit accusing the company’s directors of failing to prevent the unlawful distribution of opioids…
Study Finds CPAP May Harm Low-Risk Sleep Apnea Patients
Categories: Philips CPAP/BiPAP/ASV Sleep Apnea Machines
A new study has cast doubt on the long-standing belief that continuous positive airway pressure (CPAP) machines significantly reduce heart…
FDA Adds New Warnings on Long-Term Opioid Risks
Categories: Opioids
Federal regulators have raised concerns that many opioid medications were approved for prolonged use without sufficient clinical evidence confirming their safety.
…